{"id":"NCT00069784","sponsor":"Sanofi","briefTitle":"The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention)","officialTitle":"A Multicenter, International Randomized, 2x2 Factorial Design Study to Evaluate the Effects of Lantus (Insulin Glargine) Versus Standard Care, and of Omega-3 Fatty Acids Versus Placebo, in Reducing Cardiovascular Morbidity and Mortality in High Risk People With Impaired Fasting Glucose (IFG), Impaired Glucose Tolerance (IGT) or Early Type 2 Diabetes Mellitus: The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2003-08","primaryCompletion":"2011-12","completion":"2011-12","firstPosted":"2003-10-06","resultsPosted":"2013-01-25","lastUpdate":"2013-01-31"},"enrollment":12537,"design":{"allocation":"RANDOMIZED","model":"FACTORIAL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes Mellitus, Non-Insulin-Dependent"],"interventions":[{"type":"DRUG","name":"insulin glargine (HOE901)","otherNames":["Lantus速"]},{"type":"DRUG","name":"omega-3 polyunsaturated fatty acids (PUFA)","otherNames":["Omacor速"]},{"type":"DRUG","name":"placebo","otherNames":[]},{"type":"DEVICE","name":"reusable pen device for insulin injection","otherNames":["OptiPen速 Pro 1"]}],"arms":[{"label":"Insulin glargine + omega-3 polyunsaturated fatty acids","type":"EXPERIMENTAL"},{"label":"Insulin glargine + placebo","type":"EXPERIMENTAL"},{"label":"Standard care + omega-3 polyunsaturated fatty acids","type":"EXPERIMENTAL"},{"label":"Standard care + placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The primary objectives of the ORIGIN study were:\n\n* To determine whether insulin glargine-mediated normoglycemia can reduce cardiovascular morbidity and/or mortality in people at high risk for vascular disease with either Impaired Fasting Glucose (IFG), Impaired Glucose Tolerance (IGT) or early type 2 diabetes;\n* To determine whether omega-3 fatty acids can reduce cardiovascular mortality in people with IFG, IGT or early type 2 diabetes.\n\nThe secondary objectives of the insulin glargine study were to determine if insulin glargine-mediated normoglycemia can reduce:\n\n* total mortality (all causes);\n* the risk of diabetic microvascular outcomes;\n* the rate of progression of IGT or IFG to type 2 diabetes.","primaryOutcome":{"measure":"Composite of the First Occurrence of Cardiovascular (CV) Death, Nonfatal Myocardial Infarction (MI) or Nonfatal Stroke","timeFrame":"from randomization until study cut-off date (median duration of follow-up: 6.2 years)","effectByArm":[{"arm":"Insulin Glargine","deltaMin":1041,"sd":null},{"arm":"Standard Care","deltaMin":1013,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.6273"}]},"eligibility":{"minAge":"50 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":10,"exclusionCount":null},"locations":{"siteCount":40,"countries":["United States","Argentina","Australia","Austria","Belarus","Bermuda","Brazil","Canada","Chile","China","Colombia","Croatia","Denmark","Estonia","Finland","France","Germany","Hungary","India","Ireland","Israel","Italy","Latvia","Lithuania","Mexico","Netherlands","Norway","Philippines","Poland","Romania","Russia","Slovakia","South Africa","South Korea","Spain","Sweden","Switzerland","Turkey (T端rkiye)","United Kingdom","Venezuela"]},"refs":{"pmids":["18082485","20546261","21631894","22323416","22686416","22686415","40490702","36854916","35431237","35101326","34676424","33752449","32019855","31928076","31727687","31235487","30425095","30337280","30262460","30203580","30012324","28895655","28842165","28837885","28403644","28368516","27974345","26681720","26518765","24898834","24771090","24768457","24684774","24574355","23999452","23656980","23564916"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":303,"n":6231},"commonTop":[]}}